BioWorld

May 10, 2006

View Archived Issues

Merck Buying GlycoFi For $400M, Abmaxis For $80M

Merck & Co. Inc. set in motion two definitive agreements to acquire privately held biotechnology companies GlycoFi Inc. and Abmaxis Inc., and $400 million for $80 million, respectively, and would pay cash for both. (BioWorld Today) Read More

Avidia's Third Round: $44M For Avimer-Based Pipeline

Read More

Avicena Drug Misses Endpoint But Shows Improved Mortality

Read More

Pharmasset Files For $75M IPO; Caprion Bids To Go Public, Too

Read More

Clinic Roundup

Read More

Other News To Note

Read More

Appointments And Advancements

Read More